BridgeBio Pharma Inc

BridgeBio Pharma Inc

BBIO - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$14.65B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
BridgeBio Pharma IncBridgeBio Pharma Inc-24.7-23%19.5-1
$110.17

Target Price by Analysts

41.4% upsideBridgeBio Pharma Target Price DetailsTarget Price
$-76.74

Current Fair Value

198.5% downside

Overvalued by 198.5% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$14.65 Billion
Enterprise Value$16.47 Billion
Earnings per Share$-3.79
Beta0.97
Outstanding Shares196,029,851

Return

Return on Equity22.67%ROE
Return on Assets-46.84%
Return on Invested Capital-133.95%

Valuation & Multiples

P/E Ratio-24.65P/E Ratio
PEG35.75PEG
Price to Sales19.47Price to Sales
Price to Book Ratio-5.99Price to Book Ratio
Enterprise Value to Revenue18.1
Enterprise Value to EBIT-37.65
Enterprise Value to Net Income-29
Total Debt to Enterprise0.15
Debt to Equity-0.99Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 4, 2026
EPS Estimate
$-0.57
Consensus analyst estimate
Revenue Estimate
$267.31 M
Consensus analyst estimate

Next Earnings Call

Expected Date
February 23, 2027
EPS Estimate
$-0.58
Consensus analyst estimate
Revenue Estimate
$310.85 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 16.52%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.98%▼ 99.31%
Total Invested$126.92M▼ 99.13%
Investors Holding108▼ 406.00%

About BridgeBio Pharma Inc

CEO: Neil Kumar

BridgeBio Pharma Insider Information FAQ

Stockcircle tracks 12 top investors with a current 13F position in BridgeBio Pharma. Notable holders include Bridgewater Associates. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 8 top investors increased or opened positions and 4 top investors reduced or sold among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 18 open-market insider sales for BridgeBio Pharma in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Stockcircle lists 6 politician trade disclosures tied to BridgeBio Pharma in the last twelve months, drawn from periodic financial disclosure reports. 1 politician traded BridgeBio Pharma in the past year.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.